Journal of Antimicrobial Chemotherapy (2002) 50, 73-77
© 2002 The British Society for Antimicrobial Chemotherapy
Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement
1 Bristol Centre for Antimicrobial Research & Evaluation and 3 Department of Orthopaedics, Southmead Hospital, Bristol BS10 5NB, UK; 2 Institute of Antibiotics, Huashan Hospital, Fu Dan University, Shanghai 200040, Peoples Republic of China
Received 22 October 2001; returned 22 February 2002; revised 4 March 2002; accepted 21 March 2002
Twelve patients undergoing total hip replacement were given 600 mg of linezolid as a 20 min iv infusion along with conventional prophylaxis of 1 g of cefamandole immediately before surgery. Routine total hip arthroplasty was carried out, and at timed intervals during surgery samples of bone, fat, muscle and blood were collected for assay by high-performance liquid chromatography analysis. Samples of the haematoma fluid that formed around the operation site and further blood samples for assay were also collected at timed intervals following the operation. The penetration of linezolid into bone was rapid, with mean concentrations of 9.1 mg/L (95% CI 7.7–10.6 mg/L) achieved at 10 min after the infusion, decreasing to 6.3 mg/L (95% CI 3.9–8.6 mg/L) at 30 min. Correction for the simultaneous blood concentrations gave mean values for bone penetration of 51% at 10 min, 60% at 20 min and 47% at 30 min. Although the penetration of linezolid into fat was also rapid, mean concentrations and degree of penetration were c. 60% of those in bone; at 10 min they were 4.5 mg/L (95% CI 3.0–6.1 mg/L; penetration 27%); at 20 min they were 5.2 mg/L (95% CI 4.0–6.4 mg/L; penetration 37%); and at 30 min, 4.1 mg/L (95% CI 3.3–4.8 mg/L; penetration 31%). For muscle the corresponding values were 10.4 mg/L (95% CI 8.1–12.7 mg/L; penetration 58%) at 10 min, 13.4 mg/L (95% CI 10.2–16.5 mg/L; penetration 94%) at 20 min and 12.0 mg/L (95% CI 9.2–14.8 mg/L; penetration 93%) at 30 min. Mean concentrations of linezolid in the haematoma fluid drained from around the operation site were 8.2 mg/L at 6–8 h and 5.6 mg/L at 10–12 h after the infusion, and 7.0 mg/L at 2–4 h following a second 600 mg infusion given 12 h post-operatively. We conclude that linezolid exhibits rapid penetration into bone, fat and muscle of patients undergoing hip arthroplasty, to achieve levels in excess of its MIC for susceptible organisms (
4 mg/L); therapeutic concentrations were maintained in the haematoma fluid that surrounds the operation site for >16 h.
* Corresponding author. Tel: +44-117-9595653; Fax: +44-117-9593217; E-mail: Lovering_a{at}southmead.swest.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. E. Stein, S. Schooley, C. A. Peloquin, A. Missavage, and D. H. Havlichek Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections J. Antimicrob. Chemother., October 1, 2007; 60(4): 819 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, and C. Kloft Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2455 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. McKee, M. Ferguson, A. T. Bentley, and T. A. Marks Inhibition of Mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2042 - 2049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J I Prydal, D R Jenkins, A Lovering, and A Watts The pharmacokinetics of linezolid in the non-inflamed human eye Br J Ophthalmol, November 1, 2005; 89(11): 1418 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weigelt, K. Itani, D. Stevens, W. Lau, M. Dryden, C. Knirsch, and the Linezolid CSSTI Study Group Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2260 - 2266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dehghanyar, C. Burger, M. Zeitlinger, F. Islinger, F. Kovar, M. Muller, C. Kloft, and C. Joukhadar Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple Doses Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2367 - 2371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bassetti, F. Vitale, G. Melica, E. Righi, A. Di Biagio, L. Molfetta, F. Pipino, M. Cruciani, and D. Bassetti Linezolid in the treatment of Gram-positive prosthetic joint infections J. Antimicrob. Chemother., March 1, 2005; 55(3): 387 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E Stein, S. L Schooley, C. A Peloquin, V. Kak, D. H Havlichek, D. M Citron, K. L Tyrrell, and E. J. Goldstein Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis Ann. Pharmacother., March 1, 2005; 39(3): 427 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Razonable, D. R. Osmon, and J. M. Steckelberg Linezolid Therapy for Orthopedic Infections Mayo Clin. Proc., September 1, 2004; 79(9): 1137 - 1144. [Abstract] [PDF]
|
|
|
|
|
|
I. Mogenet, S. Raetz-Dillon, J.-M. Canonge, M. Archambaud, and E. Bonnet Successful Treatment of Staphylococcus epidermidis Hip Prosthesis Infection with Oral Linezolid Ann. Pharmacother., June 1, 2004; 38(6): 986 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Rodriguez, L. Cebrian, M. Lopez, M. Ruiz, I. Jimenez, and G. Royo Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis J. Antimicrob. Chemother., March 1, 2004; 53(3): 441 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kutscha-Lissberg, U. Hebler, G. Muhr, and M. Koller Linezolid Penetration into Bone and Joint Tissues Infected with Methicillin-Resistant Staphylococci Antimicrob. Agents Chemother., December 1, 2003; 47(12): 3964 - 3966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Honeybourne, C. Tobin, G. Jevons, J. Andrews, and R. Wise Intrapulmonary penetration of linezolid J. Antimicrob. Chemother., June 1, 2003; 51(6): 1431 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Moise, A. Forrest, M. C. Birmingham, and J. J. Schentag The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin J. Antimicrob. Chemother., December 1, 2002; 50(6): 1017 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rana, I. Butcher, P. Grigoris, C. Murnaghan, R. A. Seaton, and C. M. Tobin Linezolid penetration into osteo-articular tissues J. Antimicrob. Chemother., November 1, 2002; 50(5): 747 - 750. [Abstract] [Full Text] [PDF]
|
|